Navigation Links
3SBio Inc. Announces Preliminary Third Quarter 2008 Results
Date:10/31/2008

-- Expects One-Time Impairment Charge of RMB19.0 million (US$2.7 million)

-- Affirms 2008 Full Year Guidance

SHENYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced today that it expects to recognize a one-time impairment charge of approximately RMB19.0 million (US$2.7 million) in the third quarter 2008 and affirmed its 2008 full year guidance.

Preliminary Third Quarter 2008 Selected Unaudited Financial Results

The Company's financial statements for the three months ended September 30, 2008 have not been finalized and are subject to completion of its normal quarter-end closing procedures. Therefore, the preliminary selected unaudited financial data set forth below may be subject to adjustment. As a consequence, actual results could differ materially from the expected results provided.

For the third quarter 2008, 3SBio expects total net revenues of approximately RMB68.2 million (US$10.0 million), representing an increase of 21.6% over the third quarter 2007. For the same period, 3SBio expects to recognize a one-time impairment loss of approximately RMB19.0 million (US$2.7 million). This impairment loss was related to a US$3.0 million aggregate principal amount of Floating Rate Credit Linked Notes due on January 21, 2009 (the "Notes") held by the Company. As a result, net income for the third quarter 2008 is expected to be approximately RMB1.9 million (US$0.3 million), or US$0.01 per ADS.

The Notes, issued by UBS AG, Jersey Branch (the "Issuer"), are linked to credit of Lehman Brot
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines ... forecast of revenue. The Automatic patient billing market in ... by 2018, at a developing CAGR of 7.2% from ... the Asian Automatic patient billing market, to get an ... a glimpse of the segmentation of this market in ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... EraGen Biosciences, Inc. announced today that it has developed ... technology. The test is now in the hands of USAMRIID ... being shipped to WHO Central Public Health Laboratory (UK) and ... recent sequencing of the SARS genome, EraGen went to work ...
... being held to solicit public sentiment on Assembly Bill ... . The bills were introduced to the state legislature in ... parthenogenesis (the process of manipulating the genetic material of a ... from any other cell, in a way that causes the ...
... April 29 Berbee Information Networks Corporation, a leading Midwest ... announced today that it has been selected by Microsoft ... 2003 and Visual Studio .NET 2003 Launch. , ... Midwest Express Center inMilwaukee, Wisconsin, Berbee will speak in ...
Cached Biology Technology:EraGen Biosciences Ships SARS Diagnostic Test in Record Time 2Public Hearing Held for controversial anti-cloning bills 2Public Hearing Held for controversial anti-cloning bills 3Public Hearing Held for controversial anti-cloning bills 4
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... computational and experimental researchers is needed to make ... understanding how epigenetic marks contribute to regulation of ... organised by the European Science Foundation (ESF), Computational ... Transcription Regulation. , Epigenetics studies features of the ...
... April) at the UK National Stem Cell Network Annual ... University describes his work to investigate a mechanism that ... Together with his colleague Owen Sansom from the University ... wrong and a crucial gene called Apc is lost ...
... into the brain could dramatically reduce damage caused by ... Meeting will hear today (10 April). Speaking at ... Institute of Psychiatry will explain how combining scaffold microparticles ... tissue. Strokes cause temporary loss of blood supply ...
Cached Biology News:Computation to unravel how genes are regulated and shed light on how cells become different 2Computation to unravel how genes are regulated and shed light on how cells become different 3Stem cells and cancer: cancer pathways that also control the adult stem cell population 2Scientists ask whether microscaffolding can help stem cells rebuild brain after stroke damage 2
... 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. PROTECT ... potent inhibitor of MMP-2 that acts in ... 1.7 μM). Purity: ≥98% by TLC. ... in solution, reconstitute just prior to use. ...
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
Goat polyclonal to DRAK2...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
Biology Products: